Osteoporosis and other adverse body composition changes during androgen deprivation therapy for prostate cancer

Cancer and Metastasis Reviews

Volumn 21, Issue 2, 2002, Pages 159-166

  Smith, Matthew R ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Androgen deprivation therapy; Bicalutamide; Bone; Estrogen; Fat; Fracture; Gonadotropin releasing hormone agonist; Muscle; Osteoporosis; Prostate cancer

Indexed keywords

ALENDRONIC ACID; BICALUTAMIDE; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; ESTROGEN; GONADORELIN AGONIST; PAMIDRONIC ACID; VITAMIN D; ZOLEDRONIC ACID; ANTIANDROGEN; GONADORELIN;

ALCOHOL CONSUMPTION; ARTICLE; BODY COMPOSITION; BODY FAT; BODY WEIGHT DISORDER; BONE DENSITY; BONE METABOLISM; BONE MINERAL; BREAST TENDERNESS; DIET; DRUG EFFICACY; ESTROGEN BLOOD LEVEL; EXERCISE; FATIGUE; FRACTURE; HOT FLUSH; HUMAN; LIFESTYLE; MALE; MUSCLE MASS; ORCHIECTOMY; OSTEOLYSIS; OSTEOPOROSIS; PRIORITY JOURNAL; PROSTATE CANCER; QUALITY OF LIFE; SMOKING CESSATION; VITAMIN SUPPLEMENTATION; WEIGHT BEARING; CHEMICALLY INDUCED DISORDER; DRUG EFFECT; DRUG POTENTIATION; PROSTATE TUMOR; REVIEW;

ANDROGEN ANTAGONISTS; BODY COMPOSITION; GONADOTROPIN-RELEASING HORMONE; HUMANS; MALE; ORCHIECTOMY; OSTEOPOROSIS; PROSTATIC NEOPLASMS;

EID: 0036432859     PISSN: 01677659     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1020840311573     Document Type: Article

References (63)

1. Siddiqui NA, Shetty KR, Duthie EH Jr: Osteoporosis in older men: Discovering when and how to treat it. Geriatrics 54: 20-22, 27-28, 30, 1999
2. Seeman E: The structural basis of bone fragility in men. Bone 25: 143-147, 1999
3. Cummings SR, Black DM, Nevitt MC, Browner WS, Cauley JA, Genant HK, Mascioli SR, Scott JC, Seeley DG, Steiger P: Appendicular bone density and age predict hip fracture in women. The study of osteoporotic fractures research group. JAMA 263: 665-668, 1990
4. Cummings SR, Black DM, Nevitt MC, Browner W, Cauley J, Ensrud K, Genant HK, Palermo L, Scott J, Vogt TM: Bone density at various sites for prediction of hip fractures. The study of osteoporotic fractures research group. Lan 341: 72-75, 1993
5. Gardsell P, Johnell O, Nilsson BE: The predictive value of forearm bone mineral content measurements in men. Bone 11: 229-232, 1990
6. Seeley DG, Browner WS, Nevitt MC, Genant HK, Scott JC, Cummings SR: Which fractures are associated with low appendicular bone mass in elderly women? The study of osteoporotic fractures research group. Ann Intern Med 115: 837-842, 1991
7. Eastell R: Treatment of postmenopausal osteoporosis. N Engl J Med 338: 736-746, 1998
8. Kanis JA, Melton LJ 3rd, Christiansen C, Johnston CC, Khaltaev N: The diagnosis of osteoporosis. J Bone Miner Res 9: 1137-1141, 1994
9. Bilezikian JP: Osteoporosis in men. J Clin Endocrinol Metab 84: 3431-3434, 1999
10. Smith MR, McGovern FJ, Fallon MA, Schoenfeld D, Kantoff PW, Finkelstein JS: Low bone mineral density in hormone-naive men with prostate carcinoma. Cancer 91: 2238-2245, 2001
11. Szulc P, Marchand F, Duboeuf F, Delmas PD: Cross-sectional assessment of age-related bone loss in men: The MINOS study. Bone 26: 123-129, 2000
12. Snyder PJ, Peachey H, Berlin JA, Hannoush P, Haddad G, Dlewati A, Santanna J, Loh L, Lenrow DA, Holmes JH, Kapoor SC, Atkinson LE, Strom BL: Effects of testosterone replacement in hypogonadal men. J Clin Endocrinol Metab 85: 2670-2677, 2000
13. Zojer N, Keck AV, Pecherstorfer M: Comparative tolerability of drug therapies for hypercalcaemia of malignancy. Drug Saf 21: 389-406, 1999
14. Zmuda JM, Cauley JA, Glynn NW, Finkelstein JS: Posterior-anterior and lateral dual-energy X-ray absorptiometry for the assessment of vertebral osteoporosis and bone loss among older men. J Bone Miner Res 15: 1417-1424, 2000
15. Finkelstein JS, Cleary RL, Butler JP, Antonelli R, Mitlak BH, Deraska DJ, Zamora-Quezada JC, Neer RM: A comparison of lateral versus anterior-posterior spine dual energy X-ray absorptiometry for the diagnosis of osteopenia. J Clin Endocrinol Metab 78: 724-730, 1994
16. Grampp S, Jergas M, Gluer CC, Lang P, Brastow P, Genant HK: Radiologic diagnosis of osteoporosis. Current methods and perspectives. Radiol Clin North Am 31: 1133-1145, 1993
17. Pacifici R, Rupich R, Griffin M, Chines A, Susman N, Avioli LV: Dual energy radiography versus quantitative computer tomography for the diagnosis of osteoporosis. J Clin Endocrinol Metab 70: 705-710, 1990
18. Delmas PD, Eastell R, Garnero P, Seibel MJ, Stepan J: The use of biochemical markers of bone turnover in osteoporosis. Committee of scientific advisors of the international osteoporosis foundation. Osteoporos Int 11: S2-S17, 2000
19. Schutte HE, Park WM: The diagnostic value of bone scintigraphy in patients with low back pain. Skeletal Radiol 10: 1-4, 1983
20. Orwoll ES: Osteoporosis in men. Endocrinol Metab Clin North Am 27: 349-367, 1998
21. Daniell HW: Osteoporosis after orchiectomy for prostate cancer. J Urol 157: 439-444, 1997
22. Townsend MF, Sanders WH, Northway RO, Graham SD Jr: Bone fractures associated with luteinizing hormone-releasing hormone agonists used in the treatment of prostate carcinoma. Cancer 79: 545-550, 1997
23. Hatano T, Oishi Y, Furuta A, Iwamuro S, Tashiro K: Incidence of bone fracture in patients receiving luteinizing hormone-releasing hormone agonists for prostate cancer. BJU Int 86: 449-552, 2000
24. Oefelein MG, Ricchuiti V, Conrad W, Seftel A, Bodner D, Goldman H, Resnick M: Skeletal fracture associated with androgen suppression induced osteoporosis: The clinical incidence and risk factors for patients with prostate cancer. J Urol 166: 1724-1728, 2001
25. Burton BT, Foster WR, Hirsch J, Van Itallie TB: Health implications of obesity: An NIH Consensus Development Conference. Int J Obes 9: 155-170, 1985
26. Goldray D, Weisman Y, Jaccard N, Merdler C, Chen J, Matzkin H: Decreased bone density in elderly men treated with the gonadotropin-releasing hormone agonist decapeptyl (D-Trp6-GnRH). J Clin Endocrinol Metab 76: 288-290, 1993
27. Eriksson S, Eriksson A, Stege R, Carlstrom K: Bone mineral density in patients with prostatic cancer treated with orchidectomy and with estrogens. Calcif Tissue Int 57: 97-99, 1995
28. bone mineral densities in men treated for prostate carcinoma: Longitudinal evaluation and response to intermittent cyclic etidronate therapy. Cancer 83: 1561-1566, 1998
29. Maillefert JF, Sibilia J, Michel F, Saussine C, Javier RM, Tavernier C: Bone mineral density in men treated with synthetic gonadotropin-releasing hormone agonists for prostatic carcinoma. J Urol 161: 1219-1222, 1999
30. Daniell HW, Dunn SR, Ferguson DW, Lomas G, Niazi Z, Stratte PT: Progressive osteoporosis during androgen deprivation therapy for prostate cancer. J Urol 163: 181-186, 2000
31. Giovannucci E, Rimm EB, Wolk A, et al.: Calcium and fructose intake in relation to risk of prostate cancer. Cancer Res 58: 442-447, 1998
32. Chan JM, Giovannucci E, Andersson SO, Yuen J, Adami HO, Wolk A: Dairy products, calcium, phosphorous, vitamin D, and risk of prostate cancer (Sweden). Cancer Causes Control 9: 559-566, 1998
33. Giovannucci E: Dietary influences of 1,25(OH)2 vitamin D in relation to prostate cancer: A hypothesis. Cancer Causes Control 9: 567-582, 1998
34. Smith MR, McGovern FJ, Zietman AL, et al.: Pamidronate to prevent bone loss in men receiving gonadotropin releasing hormone agonist therapy for prostate cancer. N Engl J Med 345: 948-955, 2001
35. Orwoll E, Ettinger M, Weiss S, Miller P, Kendler D, Graham J, Adami S, Weber K: Alendronate for the treatment of osteoporosis in men. N Engl J Med 343: 604-610, 2000
36. Novartis-Oncology. Data on file. 2001
37. Slemenda CW, Longcope C, Zhou L, Hui SL, Peacock M, Johnston CC: Sex steroids and bone mass in older men. Positive associations with serum estrogens and negative associations with androgens. J Clin Invest 100: 1755-1759, 1997
38. Khosla S, Melton LJ 3rd, Atkinson EJ, O'Fallon WM, Klee GG, Riggs BL: Relationship of serum sex steroid levels and bone turnover markers with bone mineral density in men and women: A key role for bioavailable estrogen. J Clin Endocrinol Metab 83: 2266-2274, 1998
39. Greendale GA, Edelstein S, Barrett-Connor E: Endogenous sex steroids and bone mineral density in older women and men: The Rancho Bernardo Study. J Bone Miner Res 12: 1833-1843, 1997
40. Barrett-Connor E, Mueller JE, von Muhlen DG, Laughlin GA, Schneider DL, Sartoris DJ: Low levels of estradiol are associated with vertebral fractures in older men, but not women: The Rancho Bernardo Study. J Clin Endocrinol Metab 85: 219-223, 2000
41. Smith EP, Boyd J, Frank GR, Takahashi H, Cohen RM: Estrogen resistance caused by a mutation in the estrogen-receptor gene in a man. N Engl J Med 331: 1056-1061, 1994
42. Morishima A, Grumbach MM, Simpson ER, Fisher C, Qin K: Aromatase deficiency in male and female siblings caused by a novel mutation and the physiological role of estrogens. J Clin Endocrinol Metab 80: 3689-3698, 1995
43. Bilezikian JP, Morishima A, Bell J, Grumbach MM: Increased bone mass as a result of estrogen therapy in a man with aromatase deficiency. N Engl J Med 339: 599-603, 1998
44. Robson M, Dawson N: How is androgen-dependent metastatic prostate cancer best treated? Hematol Oncol Clin North Am 10: 727-747, 1996
45. Moul JW: Hormonal therapy options for biochemical recurrence of prostate cancer after local therapy. Mol Urol 4: 267-272, 2000
46. Iversen P, Tyrrell CJ, Kaisary AV, Anderson JB, Baert L, Tammela T, Chamberlain M, Carroll K: Casodex (bicalutamide) 150-mg monotherapy compared with castration in patients with previously untreated nonmetastatic prostate cancer: Results from two multicenter randomized trials at a median follow-up of 4 years. Urology 51: 389-396, 1998
47. Tyrrell CJ, Kaisary AV, Iversen P, et al.: A randomised comparison of 'Casodex' (bicalutamide) 150 mg monotherapy versus castration in the treatment of metastatic and locally advanced prostate cancer. Eur Urol 33: 447-456, 1998
48. Boccardo F, Rubagotti A, Barichello M, et al.: Bicalutamide monotherapy versus flutamide plus goserelin in prostate cancer patients: Results of an Italian prostate cancer project study. J Clin Oncol 17: 2027-2038, 1999
49. Verhelst J, Denis L, Van Vliet P, et al.: Endocrine profiles during administration of the new non-steroidal anti-androgen Casodex in prostate cancer. Clin Endocrinol (Oxf) 41: 525-530, 1994
50. Abrahamsson PA: Treatment of locally advanced prostate cancer - A new role for antiandrogen monotherapy? Eur Urol 39: 22-28, 2001
51. Vermeulen A, Goemaere S, Kaufman JM: Testosterone, body composition and aging. J Endocrinol Invest 22: 110-116, 1999
52. Snyder PJ, Peachey H, Hannoush P, Berlin JA, Loh L, Lenrow DA, Holmes JH, Dlewati A: Effect of testosterone treatment on body composition and muscle strength in men over 65 years of age. J Clin Endocrinol Metab 84: 2647-2653, 1999
53. Bhasin S, Storer TW, Javanbakht M, et al.: Testosterone replacement and resistance exercise in HIV-infected men with weight loss and low testosterone levels. JAMA 283: 763-770, 2000
54. Grinspoon S, Corcoran C, Stanley T, Baaj A, Basgoz N, Klibanski A: Effects of hypogonadism and testosterone administration on depression indices in HIV-infected men. J Clin Endocrinol Metab 85: 60-65, 2000
55. Reid IR, Wattie DJ, Evans MC, Stapleton JP: Testosterone therapy in glucocorticoid-treated men. Arch Intern Med 156: 1173-1177, 1996
56. Katznelson L, Finkelstein JS, Schoenfeld DA, Rosenthal DI, Anderson EJ, Klibanski A: Increase in bone density and lean body mass during testosterone administration in men with acquired hypogonadism. J Clin Endocrinol Metab 81: 4358-4365, 1996
57. Bhasin S, Storer TW, Berman N, Yarasheski KE, Clevenger B: Testosterone replacement increases fat-free mass and muscle size in hypogonadal men. J Clin Endocrinol Metab 82: 407-413, 1997
58. Tayek JA, Heber D, Byerley LO, Steiner B, Rajfer J, Swerdloff RS: Nutritional and metabolic effects of gonadotropin-releasing hormone agonist treatment for prostate cancer. Metabolism 39: 1314-1319, 1990
59. Smith JC, Bennett S, Evans LM, et al.: The effects of induced hypogonadism on arterial stiffness, body composition, and metabolic parameters in males with prostate cancer. J Clin Endocrinol Metab 86: 4261-4267, 2001
60. Smith MR, Finkelstein JS, McGovern FJ, et al.: Changes in body composition during androgen deprivation therapy for prostate cancer. J Clin Endocrinol Metab 87: 599-603, 2002
61. Stone P, Hardy J, Huddart R, A'Hern R, Richards M: Fatigue in patients with prostate cancer receiving hormone therapy. Eur J Cancer 36: 1134-1141, 2000
62. Herr HW, O'Sullivan M: Quality of life of asymptomatic men with nonmetastatic prostate cancer on androgen deprivation therapy. J Urol 163: 1743-1746, 2000
63. Potosky AL, Knopf K, Clegg LX, Albertsen PC, Stanford JL, Hamilton AS, Gilliland FD, Eley JW, Stephenson RA, Hoffman RM: Quality-of-life outcomes after primary androgen deprivation therapy: Results from the Prostate Cancer Outcomes Study. J Clin Oncol 19: 3750-3757, 2001